Drug intelligence / Profile preview

nimesulide + cetirizine

Development stage
Unknown
Lead developer
Emcee Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Onimex CZ is a combination pharmaceutical product developed and marketed by Emcee Pharmaceuticals, primarily available in the Indian market. It is formulated as a tablet containing nimesulide, a non-steroidal anti-inflammatory drug (NSAID), and cetirizine, a second-generation antihistamine. Nimesulide acts as a preferential inhibitor of cyclooxygenase-2 (COX-2), which reduces the synthesis of prostaglandins responsible for pain, fever, and inflammation. Cetirizine functions as a potent and selective antagonist of peripheral histamine H1 receptors, providing relief from allergic symptoms such as sneezing, rhinorrhea, and pruritus. This combination is typically indicated for the symptomatic management of inflammatory conditions accompanied by allergic manifestations, including the common cold, sinusitis, and upper respiratory tract infections. While nimesulide is restricted in several global markets due to concerns regarding hepatotoxicity, it remains a commonly prescribed analgesic for adults in India.

Brand names
Onimex CZ
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on nimesulide + cetirizine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nimesulide + cetirizine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call